Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $287000.0.

  • ImmunoTech's Change in Accured Expenses fell 2603.09% to $287000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$145000.0, marking a year-over-year increase of 7284.64%. This contributed to the annual value of -$1.2 million for FY2024, which is 20152.54% down from last year.
  • Latest data reveals that ImmunoTech reported Change in Accured Expenses of $287000.0 as of Q3 2025, which was down 2603.09% from -$95000.0 recorded in Q2 2025.
  • In the past 5 years, ImmunoTech's Change in Accured Expenses registered a high of $1.2 million during Q3 2023, and its lowest value of -$647000.0 during Q2 2024.
  • In the last 3 years, ImmunoTech's Change in Accured Expenses had a median value of -$95000.0 in 2025 and averaged $21454.5.
  • Per our database at Business Quant, ImmunoTech's Change in Accured Expenses plummeted by 39090.91% in 2024 and then surged by 11148.15% in 2025.
  • Over the past 3 years, ImmunoTech's Change in Accured Expenses (Quarter) stood at $265000.0 in 2023, then crashed by 250.57% to -$399000.0 in 2024, then skyrocketed by 171.93% to $287000.0 in 2025.
  • Its Change in Accured Expenses was $287000.0 in Q3 2025, compared to -$95000.0 in Q2 2025 and $62000.0 in Q1 2025.